@2024 - All Right Reserved.

Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...

Greater radiotracer uptake on PSMA-PET is associated with an increased likelihood of achieving a PSA decline in response to lutetium-177. The finding is from a study of 97 patients with mCRPC treated ...

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme The patients received Lutetium (177 Lu) rhPSMA-10.1 Injections at both ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

New indication authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) expands access to lutetium177 vipivotide tetraxetan in the UK for eligible mCRPC patients earlier in the ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy. Rahul Parikh, MD, PhD, of University of Kansas, shared his ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this video, Tanya Dorff, MD, head of the ...